U.S., Aug. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07110883) titled 'A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors' on July 14.
Brief Summary: This is an open-label, dose-escalation and cohort-expansion, multicenter Phase I study involving participants with advanced solid tumors.
Study Start Date: Aug. 15, 2024
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: SYS6023
SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.
Recruitment Status: RECRUITING
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....